ArticleeLife2020
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 70 citations in OpenAlex.
- Not only as a Cullin3 ligase adaptor, SPOP may also act as a molecular bridge.Genes & diseases · 2027Review
- Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.Research square · 2026Article
- KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Molecular cancer · 2026Review
- MYC at the tumor-immune interface: mechanisms of immune escape and immunotherapy resistance.Frontiers in immunology · 2026Review
- Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology.Genes & diseases · 2025Review
- Transforming Cancer Therapy: Unlocking the Potential of Targeting Vascular and Stromal Cells in the Tumor Microenvironment.Cancer research · 2025Review
- TME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma.Bioactive materials · 2025Article
- LINC02167 stabilizes KSR1 mRNA in an mJournal of experimental & clinical cancer research : CR · 2025Article
- Fueling the fire-a pan-cancer analysis of MYC-regulated lipid metabolism.Frontiers in cell and developmental biology · 2025Review
- Article
- Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL.Blood advances · 2024Article
- Immune evasion: An imperative and consequence of MYC deregulation.Molecular oncology · 2024Review
- Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.Nature cancer · 2024Article
- Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy.Expert reviews in molecular medicine · 2024Review
- MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.Signal transduction and targeted therapy · 2024Review
- LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions.Journal of experimental & clinical cancer research : CR · 2024Article
- Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.Cell chemical biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Renumathy Dhanasekaran *Division of Gastroenterology and Hepatology, Stanford University, Stanford, United States.ORCID 0000-0001-8819-7511
Virginie Baylot *Division of Oncology, Department of Medicine, Stanford University, Stanford, United States.ORCID 0000-0003-1313-2857
Minsoon KimDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.
Sibu KuruvillaDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.
David I BellovinDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.
Nia AdenijiDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.ORCID 0000-0002-7957-5987
Anand Rajan KdDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, United States.
Ian LaiDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.ORCID 0000-0001-8662-7290
Meital GabayDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.
Ling TongDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.ORCID 0000-0003-4634-9462
Maya KrishnanDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.
Jangho ParkDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.ORCID 0000-0002-6151-5193
Theodore HuDivision of Oncology, Department of Medicine, Stanford University, Stanford, United States.
Mustafa A BarbhuiyaRadiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, United States.ORCID 0000-0002-8046-5064
Andrew J GentlesDepartment of Medicine (Biomedical Informatics), Stanford University School of Medicine, Stanford, United States.
Kasthuri KannanDepartment of Pathology, NYU Langone Medical Center, New York, United States.
Phuoc T Tran *Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, United States.ORCID 0000-0002-0147-0376
Dean W Felsher *Division of Oncology, Department of Medicine, Stanford University, Stanford, United States.ORCID 0000-0003-2496-523X
Stanford University · USJohns Hopkins University · USNYU Langone Health · USUniversity of Iowa Hospitals and Clinics · US
Funding
Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0MTargeting the MYC Pathway for the Treatment of CancerR35CA253180 · NCI · STANFORD UNIVERSITY · PI DEAN W FELSHER · 2020 to 2026
$6.9MTumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9MIntegrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M(PQ7)Multi-scale Analysis of Tumor Microenvironment HeterogeneityR01CA208735 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2017 to 2019
$2.2MStructure-Functions Studies of Twist1-induced Radioresistance in Lung CancerR01CA166348 · NCI · JOHNS HOPKINS UNIVERSITY · PI TRAN, PHUOC T. · 2013 to 2017
$1.7MFunctional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)K08CA222676 · NCI · STANFORD UNIVERSITY · PI DHANASEKARAN, RENUMATHY · 2018 to 2022
$1.0MA pre-clinical x-ray/optical tomography-guided radiation research platform for pancreatic cancerR21CA223403 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TRAN, PHUOC T., WANG, KEN KANG-HSIN · 2018 to 2019
$386kNCATS NIH HHS UL1 TR003142NCI NIH HHS K08 CA222676NCI NIH HHS R01 CA166348NCI NIH HHS R01 CA208735NCI NIH HHS R21 CA223403NCI NIH HHS R35 CA253180NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776
Abstract
Metastasis is a major cause of cancer mortality. We generated an autochthonous transgenic mouse model whereby conditional expression of
Indexed as
Gene Expression Regulation, NeoplasticImmunity, InnateAnimalsCell Line, TumorChemokine CCL2Epithelial-Mesenchymal TransitionFibrosisHumansInterleukin-13MacrophagesMiceMice, TransgenicNeoplasm MetastasisNeoplasmsNeoplasm TransplantationNuclear ProteinsCCL2 protein, humanCcl2 protein, mouseChemokine CCL2Interleukin-13MYC protein, humanMyc protein, mouseNuclear ProteinsProto-Oncogene Proteins c-mycTWIST1 protein, humanTwist1 protein, mouseTwist-Related Protein 1cancer biologycytokineshumanliver cancermacrophagesmetastasismouseMYCTwist1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.